Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis by Reither, Klaus et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary 
tuberculosis
Klaus Reither*1,2, Elmar Saathoff1, Jutta Jung1,2, Lilian T Minja2, 
Inge Kroidl1,2, Eiman Saad1,2, Jim F Huggett3, Elias N Ntinginya2, 
Lucas Maganga2, Leonard Maboko2 and Michael Hoelscher1,2
Address: 1Department of Infectious Diseases and Tropical Medicine, Klinikum of the Ludwig-Maximilians-University of Munich, Munich, 
Germany, 2NIMR-Mbeya Medical Research Programme (MMRP), Mbeya, United Republic of Tanzania and 3Centre for Infectious Diseases and 
International Health, Windeyer Institute for Medical Sciences, University College London, London, UK
Email: Klaus Reither* - kreither@mmrp.org; Elmar Saathoff - saathoff@lrz.uni-muenchen.de; Jutta Jung - jjung@mmrp.org; 
Lilian T Minja - tminja@mmrp.org; Inge Kroidl - ikroidl@mmrp.org; Eiman Saad - esaad@mmrp.org; Jim F Huggett - j.huggett@ucl.ac.uk; 
Elias N Ntinginya - nelias@mmrp.org; Lucas Maganga - lmaganga@mmrp.org; Leonard Maboko - lmaboko@mmrp.org; 
Michael Hoelscher - hoelscher@lrz.uni-muenchen.de
* Corresponding author    
Abstract
Background: The development and evaluation of rapid and accurate new diagnostic tools is
essential to improve tuberculosis (TB) control in developing countries. In a previous study, the first
release of a urine LAM-ELISA by Chemogen (Portland, USA) has been evaluated with a promising
sensitivity and specificity for the diagnosis of pulmonary TB. In the present study, the now
commercially available assay has been clinically assessed regarding its diagnostic value alone and in
combination with clinical co-factors.
Methods: The test was applied to two urine samples from 291 consecutively enrolled Tanzanian
patients with suspected pulmonary tuberculosis. The participants were subsequently assigned to
classification groups according to microbiological, clinical and radiological findings at recruitment
and during a maximum follow up period of 56 days.
Results: Only 35 out of 69 pulmonary TB cases -confirmed by smear microscopy and/or solid
culture and/or liquid culture- showed at least one positive LAM-ELISA result (sensitivity 50.7%).
The sensitivity was noticeably higher in females (66.7%) and in HIV positive participants (62.0%).
The specificity amounted to 87.8% and was determined in participants with negative results in all
microbiological tests and with sustained recovery under antibiotic treatment at day 56. Correlation
with urinalysis revealed that proteinuria was significantly and positively associated with LAM-
positivity (P = 0.026).
Conclusion: This commercially available generation of LAM-ELISA does not appear to be useful
as an independent diagnostic test for pulmonary tuberculosis. The question whether the assay is
suitable as a supplemental device in the diagnosis of HIV-associated TB, requires further
investigations.
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Background
Tuberculosis (TB) remains a serious global public health
problem, primarily in developing countries affected by
the HIV epidemic. Globally, 9.2 million new cases and 1.6
million deaths caused by tuberculosis (TB) were estimated
only for the year 2006 [1]. An efficient TB control pro-
gramme requires early and accurate diagnosis for screen-
ing, confirmation and the subsequent initiation of
treatment. At present, the diagnosis of an active mycobac-
terial infection in low-income areas relies mainly on clin-
ical examination, radiological findings, and identification
of acid-fast bacilli in unprocessed sputum using a conven-
tional light microscope. The sensitivity of sputum micros-
copy to identify active pulmonary TB is low since more
than 10,000 bacilli per ml sputum are needed for reliable
detection. Thus, smear-negative pulmonary TB is a com-
mon problem, especially in HIV infected individuals. Var-
ious studies classified 24% to 61% of HIV positive
tuberculosis patients as smear-negative pulmonary TB [2].
Mycobacterial culture, which is regarded as the diagnostic
gold standard, needs 10–100 viable bacilli per ml sputum
and is therefore much more sensitive but requires a maxi-
mum incubation time of 6–8 weeks [3]. However, in
resource constrained settings, culturing is still not wide-
spread, because it demands expensive equipment, sophis-
ticated setups and technical expertise [4]. Consequently,
there is an urgent need for rapid, field adapted, inexpen-
sive and accurate tuberculosis diagnostic tools.
In the last decades, the detection of mycobacterial anti-
gens to diagnose tuberculosis has been subject of various
research activities [5-10]. The diagnostic value of antigen
detection per se has already been proven in a number of
diseases, including malaria, influenza and bacterial men-
ingitis. For the diagnosis of tuberculosis, special attention
has been paid to lipoarabinomannan (LAM), a mycobac-
terium-specific lipopolysaccharide component of the
bacilli's cell wall. In active mycobacterial disease, LAM is
released into the blood and passes the renal barrier with-
out major changes [11]. LAM is immunogenic and sus-
pected to be an important virulence factor and therefore a
potential drug target [12,13]. Various tests have been
developed to detect LAM in serum [14,15], pleural effu-
sion [16] or sputum [17-19] of tuberculosis patients.
None of the tests is, however, widely used.
So far, the most promising approach was the detection of
LAM in urine [20-24]. Urine can be easily obtained and its
collection is often more culturally accepted than the col-
lection of sputum or blood samples. In the last years, new
assays using unprocessed urine [20] replaced a time-con-
suming approach requiring concentration and purifica-
tion of the urine [21]. Boehme et al. assessed the first
product generation of an ELISA for lipoarabinomannan in
urine (MTB ELISA Test®, Chemogen, Portland, USA). The
present study evaluated the commercially available assay
produced by Chemogen. The test is now distributed as
Clearview® TB ELISA by Inverness Medical Innovations,
Inc., Waltham, USA. The test was applied to urine from
patients with symptoms of pulmonary TB to determine its
diagnostic value alone and in combination with diagnos-
tic co-factors.
Methods
Study site and population
The study was performed at the NIMR-Mbeya Medical
Research Programme (MMRP) in collaboration with the
Regional TB and Leprosy Co-ordinator and the Mbeya
Referral Hospital. Situated in Southwest Tanzania, Mbeya
Region has a total population of approximately two mil-
lion. The region has a high burden of TB and HIV with
3601 TB cases notified in 2006 [25]. According to sentinel
surveillance [26] and confirmed by yet unpublished data
from a large population based cohort study the HIV prev-
alence in adults in the region is about 13% with a range
from 8 to 19% at different sites.
300 adults with symptoms of pulmonary tuberculosis
who had been referred from health facilities of Mbeya
urban and rural districts were recruited at the TB clinic of
the Mbeya Medical Research Programme between July
and September 2007. The following inclusion criteria
were used: persistent cough for ≥ 2 weeks and at least two
other TB associated findings (haemoptysis, chest pain,
fever, night sweats, malaise, recent unexplained weight
loss, loss of appetite, contact with TB case), the ability to
comply with study procedures such as sample collection
and no TB treatment during the past 2 months.
Study design
The recruitment of the study participants comprised inter-
views regarding medical history of participants, clinical
examination, chest radiography, HIV pre-/ and post-test
counselling, sample collection (3 or 4× sputum, 2× urine,
1× blood), HIV testing, urine dipstick testing (Multistix®
10 SG, Bayer Diagnostics, Bridgend, UK), sputum micros-
copy after Ziehl Neelsen staining, sputum culture on solid
(Löwenstein Jensen) and liquid media (BACTEC™ MGIT,
Becton Dickinson, Sparks, USA), and duplicate ELISA test-
ing for lipoarabinomannan (MTB ELISA Test®, Chem-
ogen, Portland, USA) in urine. Mycobacterial species were
identified in AFB-positive culture material using Geno-
type® Mycobacterium MTBC, CM and AS tests (Hain Lifes-
cience, Nehren, Germany). The microbiology and the
molecular biology laboratory of the Mbeya Medical
Research Programme were operating according to stand-
ardised protocols and to quality control and assurance
procedures.
Participants were assigned to well-defined classification
groups according to microbiological and clinical findings
at enrolment or during the 56 days of follow up. PatientsBMC Infectious Diseases 2009, 9:141 http://www.biomedcentral.com/1471-2334/9/141
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eligible for TB treatment were treated by the District Lep-
rosy and TB Co-ordinator following Tanzanian national
guidelines. Patients diagnosed with HIV infection were
referred for further staging and treatment to the Southern
Highland Care and Treatment Programme which is sup-
ported by the Walter Reed HIV Program (funded by the
Presidents Emergency Fund for AIDS Relief (PEPFAR)).
Smear-negative patients, who did not require immediate
TB treatment according to clinical symptoms, received
two oral antibiotic regimens in order to treat possible
other infections. The antibiotics comprised Amoxicillin
and Co-trimoxazole, or alternatively Cefpodoxime (3rd
line medication).
LAM-ELISA
The MTB-ELISA is a direct antigen sandwich immu-
noassay in a 96-well plate format. The blocked microtiter
plates are pre-coated with purified LAM-specific antibod-
ies. Participants' urines were first boiled at 95–100°C for
30 min and centrifuged for 15 min at 10000 rpm. From
each sample two aliquots of 0.1 ml of the supernatant
were applied to the same plate, incubated for 60 min at
ambient temperature, and washed with Phosphate Buff-
ered Saline pH 7.4/Tween-20 (PBST). Subsequently, 0.1
ml of undiluted conjugate solution (HRP-conjugated
LAM-specific rabbit polyclonal antibody) was added.
After 60 min incubation and washing with PBST, 0.1 ml
of the colour developer (TMB) was administered to each
well. The substrate was again incubated for 15 min at
ambient temperature, and the reaction was stopped by
adding 0.1 ml of stop solution (1 M H2SO4). The colour
development was measured at 450 nm. One low positive
and four negative controls were employed for each 96-
well plate.
Each of the two urine samples that were both collected on
day 1 of recruitment were divided into two aliquots for
duplicate analysis. Results were regarded as valid if the
mean optical density (OD) of the negative controls was
less than 0.3. Samples were re-examined if the difference
in OD between aliquots from the same sample was more
than 15% of their mean value. If the mean OD of the aliq-
uots was at least 0.1 above the mean OD of the negative
controls, the sample was considered LAM positive.
Patients were considered LAM positive if at least one of
the two urine samples tested positive as described above.
Statistical analysis
ELISA results were electronically retrieved from the ana-
lyser and stored in MS Access databases. Other study
results were recorded on case-report forms, double
entered into MS Access databases, compared and cor-
rected for data entry errors. All statistical analyses were
performed using Stata statistics software (version 10; Stata
Corp., College Station, TX).
Diagnostic test performance (Sensitivity, specificity, pre-
dictive values and likelihood ratios) was calculated only
in the groups with defined TB status (A&B as positives, C
as negatives) using the "diagt" Stata component. The diag-
nostic likelihood ratio (DLR) [27] compares the probabil-
ity of obtaining a correct test result with that of containing
an incorrect test result for positive and negative test results
respectively. Good tests should have a positive DLR that is
well above unity and a negative DLR that is close to zero.
DLR calculation uses the following formulas: positive
DLR = sensitivity/(1-specificity); negative DLR = (1-sensi-
tivity)/specificity.
The influence of HIV status, sex, CD4 count and urinalysis
results on LAM positivity was assessed in multivariate
models adjusted for several factors using Poisson regres-
sion with robust variance estimates [28,29].
Ethical considerations
The study was approved by the Mbeya Ethics and Research
Committee, Tanzania, and the National Ethical Commit-
tee/Medical Research Coordinating Committee, National
Institute for Medical Research, Tanzania. The purpose and
the procedures of the study were explained thoroughly to
the attending TB suspects. Only persons who gave volun-
tarily written informed consent in the presence of a wit-
ness were enrolled in the study.
Results
Characteristics of the study population
The 291 study participants were categorized as follows:
smear- and culture-positive for M. tuberculosis (group A;
16.5%); smear-negative, culture-positive for M. tuberculo-
sis (group B; 7.2%); smear-negative, culture-positive for
non-tuberculous mycobacteria (group B NTM; 15.5%); all
smears and cultures negative and sustained recovery
under antibiotic treatment at day 56 (group C; 28.2%); all
cultures negative, chest x-ray and clinical symptoms very
suspicious for TB (group D; 19.2%); any other possible
combination of results and loss to follow up after recruit-
ment (group I; 13.4%).
Although the number of female (151) and male partici-
pants (140) was similar in the total study population,
group A had a higher proportion of men (64.6%) and
group B a higher proportion of women (61.9%). The
median age was 36 years (interquartile range = 30 to 46
years) and 172 (59.1%) patients were HIV infected
(61.6% of females, 56.4% of males). The HIV prevalence
in group A and B combined was significantly higher than
in the remaining groups combined (Prevalence ratio =
1.319; P = 0.0098). 86.6% of the HIV infected participants
had a blood CD4 cell count of less then 350 per ml and
58.1% had a CD4 cell count below 200 per ml blood.
Interestingly, about 90% of the smear negative but cultureBMC Infectious Diseases 2009, 9:141 http://www.biomedcentral.com/1471-2334/9/141
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positive individuals were HIV positive. The HIV positives
in group A had higher CD4 counts than the HIV positives
in group B (P = 0.374). The TB prevalence in HIV positive
patients with defined TB status (groups A, B and C) was
57.5%, and 26.7% in HIV negative patients of the same
groups. 18% of all HIV-infected patients (n = 291) had
sputum smear-positive TB. Characteristics, findings at
enrolment and medical history of the 291 participants are
shown in Table 1.
Diagnostic performance of the LAM-ELISA
If at least one of the two urine samples of the patient
showed a positive LAM-ELISA result, the test was consid-
ered to indicate the presence of active tuberculosis infec-
tion in the per-patient analyses. In 89% of all patients
both urine samples were either LAM positive or negative,
only in 11% a disagreement of the two LAM-ELISA results
was found. The overall sensitivity of the LAM-ELISA in
patients with culture confirmed pulmonary M. tuberculosis
infection (groups A and B) was 50.7%. Two major factors
influenced the sensitivity considerably: sex and HIV sta-
tus. The test sensitivity in women was 67%, while it was
only 38% in men (P = 0.023). In HIV positive individuals
the sensitivity was 62% compared to 21% in HIV negative
participants. (P = 0.019) (Table 2). When combined in a
multivariate Poisson regression model with LAM sensitiv-
ity as the outcome (true positives coded as "0", false neg-
atives coded as "1"), the influence of HIV status and sex
was less prominent than in separate univariate models.
However, HIV status still had a significant association
with LAM sensitivity (P = 0.040), and the association of
sex with LAM sensitivity was still evident, although not
significant anymore (P = 0.118) (Table 3). Further multi-
variate analyses showed that the influence of CD4 count
adjusted for TB status, HIV status, sex and age on LAM-
ELISA outcome was non-significant.
LAM-ELISA positive urine samples were found in 8.9% of
the participants infected by non-tuberculous mycobacte-
ria (B NTM) and in 12.2% of the non-TB patients (C).
Therefore, the overall specificity amounts to 87.8%, being
slightly higher in men (93.9%) and HIV negative partici-
pants (91.1%). The proportion of LAM positive patients
in relation to their classification group and HIV status is
shown in Table 4.
We calculated the sensitivity and specificity of the LAM-
ELISA at different OD cut-off values. Figure 1 illustrates
the trade-offs that have to be made when trying to increase
sensitivity or specificity by lowering or raising the cut-off.
The per-sample analysis of our results showed that only
44.2% of the urine specimens from microbiologically
confirmed TB cases (A and B) were also LAM-ELISA posi-
tive, whereas 92.1% of the samples of non-TB cases (C)
were LAM-ELISA negative.
Association between performance of the LAM-ELISA and 
patient characteristics
Table 5 reflects the diagnostic performance of the LAM-
ELISA in combination with various clinical findings or
reported symptoms. The definitions of the symptoms
reported by the patients are shown in Table 6. Combining
LAM-ELISA results with patient characteristics or disease
parameters did not substantially change the overall diag-
nostic value of the test. Improvements in sensitivity and
positive predictive value were offset by impaired specifici-
ties and negative predictive values respectively. Only the
combination of LAM-positivity and fever (body tempera-
ture ≥ 37.5°C) at the enrolment visit was different in this
respect: this criterion improved test specificity from 87.8
to 98.8% and reduced the sensitivity by about 50% (from
50.7% to 23.9%). This is also reflected by a strong increase
in the positive DLR (from 4.16 to 19.6) that is not totally
offset by the increase in the negative DLR (0.56 to 0.77).
Optical density values
The maximum OD of the two urine samples from each
patient has been analysed for the classification groups and
is shown in Figure 2. Apart from some outliers, maximum
Table 1: Patient characteristics, findings at enrolment and medical history
Characteristics Findings at enrolment % (n) Symptoms during 3 months 
prior to enrolment
% (n)
Female 51.9% HIV Infection 59.1 (172) Chest pain 99.7 (290)
Mean age 38.8 years In HIV infected: Expectoration 96.6 (281)
Mean weight 53.9 kg Blood CD4 count 0–199 58.1 (100) Fever 81.4 (236)
Mean body temperature 36.7°C Blood CD4 count 200–349 28.5 (49) Body weakness 87.6 (255)
Blood CD4 count ≥ 350 13.4 (23) Night sweat 71.8 (209)
Body temperature ≥ 37.5°C 16.6 (48) Loss of appetite 49.5 (144)
BCG Scar 66.1 (191) Haemoptysis 11.7 (34)
Lymphadenopathy 8.7 (25) Oedema 3.1 (9)
History of TB 12.0 (35)
TB contact 5.2 (15)BMC Infectious Diseases 2009, 9:141 http://www.biomedcentral.com/1471-2334/9/141
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ODs above the cut-off were only reached in group A and
B. However, even in group A the median of the maximum
ODs (0.097) did not exceed the cut-off for test positivity
(0.1).
Urinalysis results and LAM-ELISA performance
The possible effect of urine parameters as determined by
dipstick testing on LAM-ELISA positivity was examined in
all samples with defined TB status (groups A, B, C; n =
302) using Poisson regression adjusted for potentially
confounding factors (gender, HIV status, TB status and
AFB smear-positivity). Of these parameters (protein, hae-
moglobin, leukocytes, nitrites, glucose, ketones, urinary
pH, specific gravity, bilirubin, urobilirubin) only pro-
teinuria had a significant influence on the LAM-positivity
(Table 7).
Discussion
Novel diagnostic approaches are urgently needed to
improve TB diagnosis and TB control. Antigen detection
methods for the diagnosis of TB have been developed as
an alternative or a supplement to microscopy, growth-
based detection, antibody tests, analysis of volatile
organic compounds or other biomarkers, and to immu-
nological assays. Detection of M. tuberculosis antigens
especially in body fluids other than sputum has the fol-
lowing theoretical advantages: a) opportunity to quantify
the organism load, b) possibility of high specificity, c)
independence of a functioning immune response, d)
applicability also in extrapulmonary TB [30]. Despite
these promising characteristics in theory, none of the
described antigen detection tests has yet been successfully
employed in broader clinical practice. In the present
Table 2: Diagnostic test performance of LAM-ELISA (groups A and B were defined as gold standard positives, Group C as negative 
controls, other groups with undefined TB status were excluded)
Sensitivity 
%
(95% CI)
Specificity
%
(95% CI)
Positive 
predictive 
value
%
(95% CI)
Negative 
predictive 
value
%
(95% CI)
Positive 
diagnostic 
likelihood ratio
(95% CI)
Negative 
diagnostic 
likelihood ratio
(95% CI)
Subgroup (n)
LAM positivity 
in at least one 
out of two urine 
samples
All
(151)
50.7
(38.4–63.0)
87.8
(78.7–94.0)
77.8
(62.9–88.8)
67.9
(58.2–76.7)
4.16
(2.23–7.78)
0.56
(0.44–0.72)
Females (79) 66.7
(47.2–82.7)
83.7
(70.3–92.7)
71.4
(51.3–86.8)
80.4
(66.9–90.2)
4.08
(2.06–8.08)
0.40
(0.24–0.67)
Males
(72)
38.5
(23.4–55.4)
93.9
(79.8–99.3)
88.2
(63.6–98.5)
56.4
(42.3–69.7)
6.35
(1.56–25.80)
0.66
(0.50–0.85)
HIV-ve (64) 21.1
(6.1–45.6)
91.1
(78.8–97.5)
50.0
(15.7–84.3)
73.2
(59.7–84.2)
2.37
(0.66–8.50)
0.87
(0.68–1.11)
HIV+ve (87) 62.0
(47.2–75.3)
83.8
(68.0–93.8)
83.8
(68.0–93.8)
62.0
(47.2–75.3)
3.82
(1.78–8.21)
0.45
(0.31–0.66)
-ve = negative | +ve = positive
Table 3: Univariate and multivariate influence of HIV status and Sex on Lam Sensitivity
Univariate Results Multivariate Results
Covariate Stratum n Prevalence ratio for 
specificity
(95% CI) p-value Prevalence ratio for 
specificity
(95% CI) p-value
HIV status
Negative 19 1 1
Positive 50 2.945 (1.193–7.272) 0.019 2.619 (1.045 – 6.561) 0.040
Sex
Female 30 1 1
Male 39 0.577 (0.359 – 0.927) 0.023 0.694 (0.440 – 1.097) 0.118
The results of a Poisson regression included only gold standard positive participants. The outcome variable (sensitivity) was coded as 1 for true 
positive LAM results and as 0 for false negative LAM results. Apart from age and sex no other predictors were included into the multivariate model.
Prevalence ratio for specificity = probability to receive a (correct) positive LAM result for TB infected patients who are HIV+ve or male, divided by 
probability to receive a (correct) positive LAM result for TB infected patients who are HIV-ve or female.BMC Infectious Diseases 2009, 9:141 http://www.biomedcentral.com/1471-2334/9/141
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study, a direct antigen-capture ELISA for mycobacterial
lipoarabinomannan in boiled and centrifuged urine is
comprehensively evaluated for its diagnostic value.
The sensitivity of the LAM-ELISA in culture confirmed TB
patients of only 50.7% was disappointingly low. The spe-
cificity of 87.8% also fell far short of expectations. Moreo-
ver, the overall test performance can not substantially
be improved by choosing a cut-off different from 0.1
(Figure 1).
The high expectations in the clinical value of the assay
were mainly raised by a previous study of our group [20],
performed in the same setting, which reported a much
higher sensitivity (80.3%) and specificity (99%). This
study by Boehme et al. recruited fewer female (151 f/140 m
vs. 95 f/136 m; P = 0.014) and more HIV-infected (172
HIV+ve/119 HIV-ve vs. 147 HIV+ve/66 HIV-ve; P = 0.023)
participants than the present trial. Nevertheless, these dif-
ferences alone can not explain the discrepant results, since
analyses in male and HIV-infected subgroups of both
studies still result in a considerably lower sensitivity and
specificity of the LAM-ELISA in our study.
Another difference between the two studies is that Boehme
et al. used only results from conventional solid media (LJ)
for overall case definitions whereas we used a combina-
tion of solid and liquid culturing methods, with its supe-
rior diagnostic precision [31]. However, our results for
sensitivity and specificity still remain similar when liquid
culture is not considered for case definitions (51.5% and
87.8% respectively).
The first published clinical evaluation of LAM-ELISA in
urine by Tessema et al. [24], showed a higher sensitivity
(81.3%) than our study, but a similar specificity (86.9%)
while using a case definition requiring the presence of at
least two AFB-positive sputum smears.
Data regarding the LAM-ELISA presented at the 16th Con-
ference on Retroviruses and Opportunistic Infections
2009 by Mutetwa et al. [32] support our findings. This
group reports an overall sensitivity of 44% and an overall
specificity of 89%.
Unlike most of the previous LAM-ELISA studies, our study
employed molecular biological differentiation between
M. tuberculosis and non-tuberculous mycobacteria (NTM)
which should actually improve the apparent sensitivity of
the test by improving the specificity of the gold-standard.
However, despite the use of more precise reference diag-
nostic, we observed a lower sensitivity instead.
The most likely explanation for the poor diagnostic per-
formance of the test is, that the changes in the assay are
accountable for the impaired sensitivity compared to pre-
vious investigations, particularly that of Boehme et al. who
used a different version of the test by the same manufac-
turer. Unfortunately, we are unable to provide informa-
tion what exactly are the differences between the two
versions of the test. The manufacturer's information on
Table 4: Positivity of LAM-ELISA in at least one out of two urine samples
Classification Total
LAM +ve
HIV -ve
LAM +ve
HIV +ve
LAM +ve
A (smear+ve/culture+ve, M. tuberculosis) 27/48 (56.3%) 4/17 (23.5%) 23/31 (74.2%)
B (smear-ve/culture+ve, M. tuberculosis) 8/21 (38.1%) 0/2 (0.0%) 8/19 (42.1%)
B NTM
(smear-ve/culture+ve, non-tuberculous mycobacteria)
4/45 (8.9%) 2/16 (12.5%) 2/29 (6.9%)
C 
(controls, all smears and cultures-ve and sustained recovery under antibiotic 
treatment at day 56)
10/82 (12.2%) 4/45 (8.9%) 6/37 (16.2%)
D (all cultures-ve, CXR and clinical symptoms very suspicious for TB) 9/56 (16.1%) 3/18 (16.7%) 6/38 (15.8%)
I (any other possible combination of results and loss to follow up after recruitment) 8/39 (20.5%) 4/21 (19.1%) 4/18 (22.2%)
+ve = positive | -ve = negative | CXR = chest x-ray
Sensitivity and specificity of the LAM-ELISA at different cut- offs Figure 1
Sensitivity and specificity of the LAM-ELISA at differ-
ent cut-offs.
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reagents and test configuration only provides a broad pic-
ture on the principle of the test, but lacks important spec-
ifications such as the type of antibodies used for antigen
capture.
Because a single-gate patient sampling strategy identifying
TB cases and the Non-TB controls in the same source pop-
ulation was used to avoid spectrum bias [33], the pre-
sented specificity values should be considered more
applicable to a real life situation than specificity data gen-
erated with healthy volunteers as the control group [20].
The real life situation is also obvious in the fact that most
of the patients were suffering from several TB associated
symptoms for more than 3 months prior to enrolment
which indicates an advanced state of diseases.
In-vitro analysis has shown that the LAM-ELISA can detect
both M. tuberculosis and non-tuberculous mycobacterial
species, but the latter only at significantly higher concen-
trations [20]. At first sight it seems that the LAM-ELISA in
our study determines mycobacterial infections other than
tuberculosis in almost 9% of the patients. However, the
Table 5: Diagnostic test performance of LAM-ELISA combined with clinical parameters (groups A and B were defined as gold standard 
positives, Group C as negative controls, other groups with undefined TB status were excluded)
Sensitivity
%
(95% CI)
Specificity
%
(95% CI)
Positive 
predictive value
%
(95% CI)
Negative 
predictive value
%
(95% CI)
Positive 
diagnostic 
likelihood ratio
(95% CI)
Negative 
diagnostic 
likelihood ratio
(95% CI)
Subgroup (n)
LAM positivity in 
at least one out of 
two urine samples 
in combination 
with
Lymphadenopathy All (149) 7.4
(2.4–16.3)
98.8
(93.3–100.0)
83.3
(35.9–99.6)
55.9
(47.4–64.2)
5.96
(0.71–49.80)
0.94
(0.87–1.01)
Body temperature 
≥ 37.5°C
All (149) 23.9
(14.3–35.9)
98.8
(93.4–100.0)
94.1
(71.3–99.9)
61.4
(52.5–69.7)
19.60
(2.67–144.0)
0.77
(0.67–0.88)
Fever* All (150) 44.9
(32.9–57.4)
91.4
(83.0–96.5)
81.6
(65.7–92.3)
66.1
(56.5–74.7)
5.20
(2.44–11.10)
0.60
(0.48–0.75)
Body weakness* All (151) 49.3
(37.0–61.6)
89.0
(80.2–94.9)
79.1
(64.0–90.0)
67.6
(57.9–76.3)
4.49
(2.32–8.70)
0.57
(0.45–0.73)
Chest pain* All (151) 50.7
(38.4–63.0)
87.8
(78.7–94.0)
77.8
(62.9–88.8)
67.9
(58.2–76.7)
4.16
(2.23–7.78)
0.56
(0.44–0.72)
Cough* All (151) 50.7
(38.4–63.0)
87.8
(78.7–94.0)
77.8
(62.9–88.8)
67.9
(58.2–76.7)
4.16
(2.23–7.78)
0.56
(0.44–0.72)
Expectoration* All (151) 47.8
(35.6–60.2)
87.8
(78.7–94.0)
76.7
(61.4–88.2)
66.7
(56.9–75.4)
3.92
(2.09–7.37)
0.59
(0.47–0.76)
Haemoptysis* All (151) 2.9
(0.4–10.1)
98.8
(93.4–100.0)
66.7
(9.4–99.2)
54.7
(46.3–62.9)
2.38
(0.22–25.70)
0.98
(0.94–1.03)
Loss of Appetite* All (151) 30.4
(19.9–42.7)
95.1
(88.0–98.7)
84.0
(63.9–95.5)
61.9
(52.8–70.4)
6.24
(2.25–17.30)
0.73
(0.62–0.86)
Night sweat* All (151) 46.4
(34.3–58.8)
92.7
(84.8–97.3)
84.2
(68.7–94.0)
67.3
(57.8–75.8)
6.34
(2.82–14.30)
0.58
(0.46–0.73)
*Within 3 months prior to enrolment according to interviews regarding medical history
Table 6: Definition of symptoms reported by the patients
Symptoms during 3 months prior to enrolment Definition
Cough Acute or recurrent or persistent, non-remitting act of coughing
Chest pain Discomfort or pain felt between the neck and the upper abdomen
Expectoration Discharging mucus or other material from the respiratory tract by coughing
Fever Subjectively or objectively (≥37.5°C) assessed rise of body temperature
Body weakness Generalized lack of strength
Night sweat Occurrence of excessive sweating at night, usually during sleep
Loss of appetite Decreased appetite despite the body's basic caloric needs
Haemoptysis Coughing up blood from the respiratory tract
Oedema Swelling of the body due to fluid retention, predominantly in the lower legs and anklesBMC Infectious Diseases 2009, 9:141 http://www.biomedcentral.com/1471-2334/9/141
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fact that a similar percentage of controls are also LAM-
ELISA positive suggests that the positive results in patients
with solely NTM infection are not really attributable to
cross-reactivity of the test.
The sensitivity of the LAM-ELISA is noticeably higher in
HIV-infected patients (62%) than in HIV-negatives
(21%); while the specificity in HIV-infected patients is
lower (84% in HIV positive vs. 91% in HIV negative).
Because the sensitivity of sputum microscopy and culture
techniques in HIV infected persons with advanced immu-
nodeficiency is low, it is be theoretically possible that false
negative gold standard assessments could have led to a
misclassification of some LAM-ELISA results and thus
caused the low specificity of the assay. However, the influ-
ence of CD4 counts on LAM-ELISA results adjusted for TB
status, HIV status, sex and age in a multivariate model was
small and far from significant. Furthermore, the group of
HIV+ve, LAM+ve TB-ve persons had relatively high CD4
counts when comparing them to HIV+ve LAM+ve TB+ve.
Consequently, this is an unlikely explanation for the low
specificity of the test.
A recently published study [34] showed that among TB
cases lower CD4 cell counts are associated with a higher
likelihood of a positive LAM-ELISA in urine, which would
make the assay a promising rapid TB diagnostic tool
among patients with advanced immunodeficiency. How-
ever, our data do not support this finding since CD4
counts were not significantly associated with the LAM-
ELISA test outcome.
LAM-ELISA seems to diagnose TB infection in patients
presenting with fever at enrolment with both high specif-
icity and high positive DLR. Further investigations on
LAM-ELISA have to establish if these findings can be gen-
eralised, helping to diagnose TB in febrile suspects. Com-
bination with other clinical parameters did not
substantially influence the overall diagnostic performance
of the LAM-ELISA.
Among the analysed urine parameters, proteinuria had a
significant positive association with LAM-positivity. Hae-
maturia also had a positive association which was how-
ever only marginally significant. This kind of interference
has not been reported yet.
In conclusion, the evaluated version of the antigen-cap-
ture LAM-ELISA does not seem to fulfil the requirements
for a stand-alone diagnostic test for pulmonary tuberculo-
sis.
In our opinion, further investigations are needed to eluci-
date if the LAM-ELISA, in this stage of development, is val-
uable as a supplemental tool for the diagnosis of HIV-
Maximum optical density of the two samples by participant  classification (median [line], interquartile range [box], upper  and lower adjacent values [whiskers], and outside values  [dots]) Figure 2
Maximum optical density of the two samples by par-
ticipant classification (median [line], interquartile 
range [box], upper and lower adjacent values [whisk-
ers], and outside values [dots]). N for each category is 
shown in Table 4; dashed line: cut-off at OD 0.1
 
0
1
2
3
4
O
D
 
m
e
a
n
 
a
b
o
v
e
 
n
e
g
a
t
i
v
e
 
c
o
n
t
r
o
l
AB B  N T M CD
Table 7: Influence of different urine parameters (according to dipstick testing) on positivity of LAM-ELISA adjusted for gender, HIV 
status, TB status and AFB smear-positivity (per sample analysis)
Finding n Prevalence ratio for LAM positivity (95% CI) p-value
Protein
≤ Trace* 260 1
> Trace 42 1.63 (1.06–2.52) 0.026
Leukocytes
≤ Trace* 249 1
> Trace 53 0.88 (0.54–1.43) 0.609
Haemoglobin
≤ Trace* 241 1
> Trace 61 1.48 (0.99–2.22) 0.057
Specific gravity
≤ 1015* 164 1
> 1015 138 1.16 (0.77–1.74) 0.484
*Baseline category for Poisson regressionBMC Infectious Diseases 2009, 9:141 http://www.biomedcentral.com/1471-2334/9/141
Page 9 of 10
(page number not for citation purposes)
associated TB. This seems particularly important, when
taking into consideration that TB is one of the most
important opportunistic infections of HIV patients and
that the sensitivity of smear microscopy in immunocom-
promised patients is low [2,30,35]. The more encouraging
earlier results for other versions of the test might indicate
that changes in its setup could improve diagnostic per-
formance considerably. It would therefore be highly desir-
able to further develop the LAM-ELISA into the field-
adapted and precise diagnostic tool that is urgently
needed for TB diagnosis and control in resource limited
settings.
Conclusion
The commercially available generation of urine LAM-
ELISA does not appear to be useful as an independent
diagnostic test for pulmonary tuberculosis.
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